´Ý±â
TaKaRa
Á¦Ç°¸í/Á¦Ç°ÄÚµå
Å°¿öµå°Ë»ö
°Ë»ö
´Ý±â
  • °í°´Áö¿ø 
  • ¾÷¹«¾È³»¦¢Á¦Ç°¹®ÀÇ
  • ÀüÈ­¹øÈ£¦¢02-2081-2510
  • Email     ¦¢support@takara.co.kr
  • ´ëÀüÁö»ç 
  • ¾÷¹«¾È³»¦¢´ëÀü/ÃæûÁö¿ª ÁÖ¹®, Á¦Ç°¹®ÀÇ
  • ÀüÈ­¹øÈ£¦¢042-828-6525
  • Email     ¦¢tkbd@takara.co.kr
  • ¾÷¹«½Ã°£¾È³»
  • [ Æò¡¡¡¡ÀÏ ] 09 : 00 ~ 18 : 00 ¦¢ [ Á¡½É½Ã°£ ] 12 : 00 ~ 13 : 00
  • Å䡤ÀÏ¿äÀÏ, °øÈÞÀÏÀº ÈÞ¹«ÀÔ´Ï´Ù.


NEWS
 Á¦¸ñ : [½ÅÁ¦Ç°] Human primary hepatocyte Àå±â¹è¾ç ¹èÁö Ãâ½Ã
ÀÛ¼ºÀÏ : 2017.11.28
 ÀÛ¼ºÀÚ : ´ÙÄ«¶óÄÚ¸®¾Æ

±âÁ¸ÀÇ ÇѰ踦 ¶Ù¾î³Ñ´Â °£¼¼Æ÷ ¹è¾ç¹èÁö

Cellartis¢ç Power¢â Primary HEP Medium (#Y20020)

 

Human primary hepatocyte´Â in-vitro »óȲ¿¡¼­ ÃÖ´ë 1ÁÖ Á¤µµ¸¸ ¹è¾çÀÌ °¡´ÉÇÏ¿© long-term assay ¹×

drug metabolism ½ÇÇè¿¡ »ç¿ëÇϱ⿡ ¸¹Àº ¾î·Á¿òÀÌ ÀÖ¾ú½À´Ï´Ù. ÇÏÁö¸¸ CellartisÀǠ÷´Ü ¹è¾ç±â¼ú·Î °³¹ßµÈ  

Cellartis¢ç Power¢â Primary HEP Medium Àº ´Ù¾çÇÑ Á¦Á¶»çÀÇ human primary hepatocyteÀ» 4ÁÖ°£ ¹è¾çÀÌ °¡´ÉÇÕ´Ï´Ù.

ÀÌÁ¦ ±âÁ¸ÀÇ ÇѰ踦 ³Ñ¾î »õ·Î¿î ¿¬±¸¿¡ µµÀüÇϼ¼¿ä!

 

Á¦Ç°Æ¯Â¡

      -       Human primary hepatocyte 4ÁÖ°£ À¯Áö ¹è¾ç °¡´É

-       ´Ù¾çÇÑ Á¦Á¶»çÀÇ human primary hepatocyte¿¡ Àû¿ë °¡´É

-       ¹è¾ç Áß CYP È°¼º ¹× metabolism À¯Áö

-       Àå±âµ¶¼º ¹× ¾à¹°µ¿ÅÂ, ¹ÙÀÌ·¯½º °¨¿°½ÇÇè °¡´É

-       °ÝÀÏ ¹èÁö±³È¯°¡´É, overlay°¡ ÇÊ¿ä ¾ø´Â °£ÆíÇÑ »ç¿ë

 

 [Á¦Ç°Á¤º¸]

Á¦Ç°¿¡ ´ëÇÑ ÀÚ¼¼ÇÑ ³»¿ëÀº Á¦Ç°¸íÀ» Ŭ¸¯ÇÏ¿© È®ÀÎÇϼ¼¿ä.

 

Á¦Á¶»ç

Á¦Ç°ÄÚµå

Á¦Ç°¸í

¿ë·®

Cellartis

Y20020

Cellartis¢ç Power¢â Primary HEP Medium

250 ml

 

 

°ü·Ã ¹®ÀÇ»çÇ×Àº ´ÙÄ«¶óÄÚ¸®¾Æ °í°´Áö¿ø¼¾ÅÍ·Î ¿¬¶ôÁÖ¼¼¿ä.

 

- TEL. 02-2081-2510

- mail. support@takara.co.kr


÷ºÎÆÄÀÏ: Technical note_Power medium_Y20020.pdf
 ¸ñ·ÏÀ¸·Î